FAS and neuroblastoma: Here, we investigated whether pharmacologically inhibiting KDM1A can cause TP53-mediated FAS re-expression on neuroblastoma cells to enable antigen-independent killing via the FAS-FASL axis by our L1CAM-specific CAR T cells.